Description

This episode aims at highlighting the importance of patient and public involvement in research. More precisely, the speakers focus on the importance of involving patients in research, practical steps to involve patients in research, and insights from EASL including engagement of patients in the EASL-Lancet Commission.

Faculty

• Marta Alonso-Peña (Moderator)
• Kate Jack (Faculty)
• Marko Korenjak (Faculty)
• Thomas Marjot (Faculty)

Related episode

• EASL Studio from EASL Congress 2023: United we stand: Global societies collaborating to beat liver disease.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In honour of Primary Biliary Cholangitis (PBC) awareness month, this EASL studio discusses the future therapy-landscape for patients by highlighting:

• The importance of correctly diagnosing PBC
• The need of addressing both symptoms and liver disease severity
• Current and future approaches for treating PBC

Faculty

• Prof. Gideon Hirschfield (Moderator)
• Prof. Ana Lleo (Faculty)
• Dr Femi Adekunle (Faculty, Advanz Pharma representative)
• Dr Stuart Kendrick (Faculty, GSK representative)
• Dr Charles A. McWherter (Faculty, CymaBay representative)
• Dr Claudia Zein (Faculty, Ipsen representative)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

This EASL Studio is supported by Advanz Pharma, CymaBay, GSK and Ipsen.

Description

This episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion covers the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm.

Faculty

• Bruno Sangro (Moderator)
• Umberto Cillo (Faculty) 
• Helen Reeves (Faculty)
• María Reig (Faculty)

This EASL Studio is supported by AstraZeneca. EASL has received no input from AstraZeneca with regards to the content of this programme.

Related episodes

• EASL Studio S5E13: Basics in decision-making for liver cancer treatment
• EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
• EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
• EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
• EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
• EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?
• EASL Studio S2E15: JHEP Live on the best animal model for HCC – Lost in translation?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research?

Faculty

• Paolo Angeli (Moderator)
• Guadalupe Garcia-Tsao (Faculty)
• Valérie Paradis (Faculty)
• Thomas Reiberger (Faculty)

Related episodes

• EASL Studio S5E5: JHEP Live: the new nomenclature for SLD: a multidisciplinary evaluation and approach
• EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
• EASL Studio S4E4: JHEP Live: Is the term ‘decompensated cirrhosis’ outdated?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.